These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 23588536)
1. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Poi MJ; Hofmeister CC; Johnston JS; Edwards RB; Jansak BS; Lucas DM; Farag SS; Dalton JT; Devine SM; Grever MR; Phelps MA Clin Pharmacokinet; 2013 Aug; 52(8):705-12. PubMed ID: 23588536 [TBL] [Abstract][Full Text] [Related]
2. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. Parmar S; Andersson BS; Couriel D; Munsell MF; Fernandez-Vina M; Jones RB; Shpall EJ; Popat U; Anderlini P; Giralt S; Alousi A; Cano P; Bosque D; Hosing C; Silva Lde P; Westmoreland M; Wathen JK; Berry D; Champlin RE; de Lima MJ J Clin Oncol; 2011 Jan; 29(3):294-302. PubMed ID: 21149654 [TBL] [Abstract][Full Text] [Related]
3. Pentostatin in steroid-refractory acute graft-versus-host disease. Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC; Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB J Clin Oncol; 2005 Apr; 23(12):2661-8. PubMed ID: 15837980 [TBL] [Abstract][Full Text] [Related]
4. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease. Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375 [TBL] [Abstract][Full Text] [Related]
5. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872 [TBL] [Abstract][Full Text] [Related]
6. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. Jacobsohn DA; Chen AR; Zahurak M; Piantadosi S; Anders V; Bolaños-Meade J; Higman M; Margolis J; Kaup M; Vogelsang GB J Clin Oncol; 2007 Sep; 25(27):4255-61. PubMed ID: 17878478 [TBL] [Abstract][Full Text] [Related]
8. Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin. Klein SA; Bug G; Mousset S; Hofmann WK; Hoelzer D; Martin H Br J Haematol; 2011 Jul; 154(1):143-6. PubMed ID: 21477160 [No Abstract] [Full Text] [Related]
9. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410 [TBL] [Abstract][Full Text] [Related]
11. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216 [TBL] [Abstract][Full Text] [Related]
13. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223 [TBL] [Abstract][Full Text] [Related]
14. Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial. Bloom AI; Shapira MY; Or R; Sasson T; Resnick IB; Zilberman I; Verstandig A; Aker M; Slavin S; Muszkat M Clin Ther; 2004 Mar; 26(3):407-14. PubMed ID: 15110133 [TBL] [Abstract][Full Text] [Related]
15. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768 [TBL] [Abstract][Full Text] [Related]
16. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Schmitt T; Luft T; Hegenbart U; Tran TH; Ho AD; Dreger P Bone Marrow Transplant; 2011 Apr; 46(4):580-5. PubMed ID: 20562925 [TBL] [Abstract][Full Text] [Related]
17. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374 [TBL] [Abstract][Full Text] [Related]
18. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057 [TBL] [Abstract][Full Text] [Related]
19. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. Sakai R; Taguri M; Oshima K; Mori T; Ago H; Adachi S; Morita S; Taniguchi S; Fukuda T; Ohashi K; Eto T; Miyamura K; Iwato K; Kobayashi N; Kanamori H; Morishima Y; Nagamura-Inoue T; Sakamaki H; Atsuta Y; Murata M Int J Hematol; 2016 Mar; 103(3):322-33. PubMed ID: 26800676 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Jacobsohn DA; Gilman AL; Rademaker A; Browning B; Grimley M; Lehmann L; Nemecek ER; Thormann K; Schultz KR; Vogelsang GB Blood; 2009 Nov; 114(20):4354-60. PubMed ID: 19745067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]